#+Title: Lysosomal Storage Disorders
#+options: title:nil toc:nil num:nil author:nil date:nil
#+latex_class: article
#+latex_class_options:[landscape]
#+latex_header: \usepackage{longtable}
#+latex_header: \usepackage[margin=0.45in]{geometry}
#+latex_header:
#+latex_header_extra:
#+description:
#+keywords:
#+subtitle:

#+CAPTION[]:Lysosomal Storage Disorder Biochemistry
#+NAME: tab:lsd
#+ATTR_LATEX: :environment longtable :float sideways
| Disease                  | Protein                                                  | Accumulation            | Biomarker              | Diagnostic             | Gene         |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Mucopolysaccharidoses*  |                                                          |                         |                        |                        |              |
| MPS I (H, H/S, S)        | \alpha-Iduronidase                                       | DS, HS                  | GAGs(U)                | E(L,F)Pd, M            | /IDUA/       |
| MPS II (Hunter)          | Iduronate sulfatase                                      | DS, HS                  | GAGs(U)                | E(L,F,P), M            | /IDS/ (XL)   |
| MPS III A (Sanfilippo A) | Heparan sulfatase                                        | HS                      | GAGs(U)                | E(F), M                | /SGSH/       |
| MPS III B (Sanfilippo B) | Acetyl-\alpha-glucosaminidase                            | HS                      | GAGs(U)                | E(L,F,S), M            | /NAGLU/      |
| MPS III C (Sanfilippo C) | \small{Acetyl-CoA:glucosamine N-acetyltransferase}       | HS                      | GAGs(U)                | E(L,F), M              | /HGSNAT/     |
| MPS III D (Sanfilippo D) | N-acetyl-glucosamine-6-sulfatase                         | HS                      | GAGs(U)                | E(L,F), M              | /GNS/        |
| MPS IVA (Morquio A)      | N-acetyl-galactosamine-6-sulfatase                       | KS, CS                  | GAGs(U)                | E(L,F), M              | /GALNS/      |
| MPS IV B (Morquio B)     | \beta-Galactosidase[fn:glb1]                             | KS                      | GAGs(U)                | E(L,F,)Pd, M           | /GLB1/       |
| MPS VI (Maroteaux-Lamy)  | Arylsulfatase B                                          | DS                      | GAGs(U)                | E(L,F)[fn:ncs], M      | /ARSB/       |
| MPS VII (Sly)            | \beta-Glucuronidase                                      | DS, HS, CS              | GAGs(U)                | E(L,F)Pd, M            | /GUSB/       |
| MPS IX (Natowicz)        | Hyaluronidase                                            | Hyluronic acid          | -                      | E(L,F), M              | /HYAL1/      |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Sphingolipidoses*       |                                                          |                         |                        |                        |              |
| Fabry                    | \alpha-Galactosidase A                                   | Gb3                     | Gb3(U)                 | E(L,F,S)Pd, M          | /GLA/ (XL)   |
| Farber                   | Acid ceramidase                                          | Ceramide                | -                      | E(L,F), M              | /ASAH1/      |
| GM1                      | \beta-Galactosidase[fn:glb1]                             | GM1 ganglioside, KS,    | Oligos(U)              | E(L,F)Pd, M            | /GLB1/       |
|                          |                                                          | oligos, glycolipids     | GAGs(U)                |                        |              |
| GM2 Tay-Sachs            | \beta-Hexosaminidase A(+\alpha+\beta)                    | GM2 ganglioside         | -                      | E(L,F,S)Pd[fn:b1], M   | /HEXA/       |
| GM2 Sandhoff             | \beta-Hexosaminidase A(\alpha +\beta+) & B(+\beta\beta+) | GM2 ganglioside, oligos | Oligos(U)              | E(L,F)Pd, M            | /HEXB/       |
| Gaucher                  | \beta-Glucocerebrosidase                                 | Glucocerebroside        | Chito[fn:chito](S)     | E(L,F), M, BM          | /GBA/        |
| Krabbe                   | Galactocerebrosidase                                     | Galactocerebroside      | Psychosine(B)          | E(L,F), M              | /GALC/       |
| MLD                      | Arylsulfatase A                                          | Sulfatides              | Sulfatides(U)          | E(L,F)Pd[fn:ncs], M    | /ARSA/       |
| Niemann-Pick A & B       | Sphingomyelinase                                         | Sphingomyelin           | Chito[fn:chito](S)     | E(F), M, BM            | /SMPD1/      |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Activators*             |                                                          |                         |                        |                        |              |
| GM2 AB variant           | GM2 activator protein                                    | GM2 ganglioside, oligos | Oligos(U)              | M                      | /GM2A/       |
| Krabbe                   | Saposin A                                                | Galactocerebroside      | Psychosine(B)          | M                      | /PSAP/       |
| MLD/Fabry                | Saposin B                                                | Sulfatides, Gb3         | Sulfatides(U), Gb3(U)  | M                      | /PSAP/       |
| Gaucher                  | Saposin C                                                | Glucocerebroside        | Chito[fn:chito](S)     | M                      | /PSAP/       |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Glycogenoses*           |                                                          |                         |                        |                        |              |
| GSD II (Pompe)           | Acid \alpha-glucosidase                                  | Glycogen                | CK(S)                  | E(L[fn:acarbose],F), M | /GAA/        |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Oligosaccharidoses*     |                                                          |                         |                        |                        |              |
| Aspartylglicosaminuria   | Glycosylasparaginase                                     | Aspartylglucosamine     | Oligos(U)              | E, M                   | /AGA/        |
| Fucosidosis              | \alpha-Fucosidase                                        | Glycoproteins,          | Oligos(U)              | E(L,F)Pd, M            | /FUCA1/      |
|                          |                                                          | glycolipids,            |                        |                        |              |
|                          |                                                          | fucoside-rich oligos    |                        |                        |              |
| \alpha-Mannosidosis      | \alpha-Mannosidase                                       | Mannose-rich oligos     | Oligos(U)              | E(L,F), M              | /MAN2B1/     |
| \beta-Mannosidosis       | \beta-Mannosidase                                        | Man(\beta1-4)GlnNAc     | Oligos(U)              | E(L,F), M              | /MANBA/      |
| Schindler                | N-acetylgalactosaminidase                                | Sialylated              | Oligos(U)              | E(L,F), M              | /NAGA/       |
|                          |                                                          | asialoglycopeptides,    |                        |                        |              |
|                          |                                                          | glycolipids             |                        |                        |              |
| ML-I (Sialidosis)        | \alpha-Neuraminidase                                     | Oligos, glycopeptides   | Bound SA(U), oligos(U) | E(F), M                | /NEU1/       |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Lipidoses*              |                                                          |                         |                        |                        |              |
| Wolman & CESD            | Acid lipase                                              | Cholesterol esters      | -                      | E(L,F), M              | /LIPA/       |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *TMP defect*             |                                                          |                         |                        |                        |              |
| *Transporters*           |                                                          |                         |                        |                        |              |
| Sialuria (Salla)         | Sialin                                                   | Sialic acid             | Free SA(U)             | M                      | /SLC17A5/    |
| Cystinosis               | Cystinosin                                               | Cystine                 | Cystine(L)             | M                      | /CTNS/       |
| Niemann-Pick C           | NPC1 or NPC2                                             | Cholesterol,            | Chito[fn:chito](S)     | Filipin, M, BM         | /NPC1/,      |
|                          |                                                          | sphingolipids           |                        |                        | /NPC2/       |
| *Structural Proteins*    |                                                          |                         |                        |                        |              |
| Danon                    | LAMP-2                                                   | Cytoplasmic debris,     | -                      | M                      | /LAMP2/ (XL) |
|                          |                                                          | glycogen                |                        |                        |              |
| Mucolipidosis IV         | Mucolipin                                                | Lipids                  | -                      | M                      | /MCOLN1/     |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Protection Defect*      |                                                          |                         |                        |                        |              |
| Galactosialidosis        | Protective protein cathepsin A                           | Sialyloligosaccharides  | Bound SA(U),           | E(F,L)[fn:ppca], M     | /CTSA/       |
|                          |                                                          |                         | oligos(U)              |                        |              |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *PTP defect*             |                                                          |                         |                        |                        |              |
| MSD                      | Formylglycine-generating enzyme                          | Sulfatides,             | Sulfatides(U),         | E[fn:msd], M           | /SUMF1/      |
|                          |                                                          | glycolipids, GAGs       | GAGs(U)                |                        |              |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Trafficking defect*     |                                                          |                         |                        |                        |              |
| ML II & III[fn:all]      | GlcNAc-1-P transferase                                   | Oligos, GAGs, lipids    | Oligos(U), GAGs(U)     | E[fn:icell], M         | /GNPTAB/,    |
| (I-cell & Pseudo Hurler) |                                                          |                         |                        |                        | /GNPT/       |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *Degradation defect*     |                                                          |                         |                        |                        |              |
| Pycnodysostosis          | Cathepsin K                                              | Bone proteins           | X-ray                  | M                      | /CTSK/       |
|--------------------------+----------------------------------------------------------+-------------------------+------------------------+------------------------+--------------|
| *NCLs*                   |                                                          |                         |                        |                        |              |
| NCL 1                    | Palmitoyl protein thioesterase                           | Saposins A and D        | EM of skin             | E, M                   | /PPT1/       |
| NCL 2                    | Tripeptidyl peptidase 1                                  | CV(c)                   | EM of skin             | E, M                   | /TPP1/       |
| NCL 3                    | CLN3, lysosomal TMP                                      | CV(c)                   | EM of skin             | M                      | /CLN3/       |
| NCL 5                    | CLN5, soluble lysosomal protein                          | CV(c)                   | EM of skin             | M                      | /CLN5/       |
| NCL 6                    | CLN6, ER TMP                                             | CV(c)                   | EM of skin             | M                      | /CLN6/       |
| NCL 7                    | CLC7, lysosomal chloride                                 | CV(c)                   | EM of skin             | M                      | /MFSD8/      |
| NCL 8                    | CLN8, ER TMP                                             | CV(c)                   | EM of skin             | M                      | /CLN8/       |
| NCL 10                   | Cathepsin D                                              | Saposins A and D        | EM of skin             | M                      | /CTSD/       |
- Abbreviations :: PTP, post-translational processing; TMP,
  transmembrane protein; MSD, multiple sulfatase deficiency; SA,
  sialic acid; CV(c), ATP synthase subunit c; Chito, chitotriosidase;
  EM, electron microscopy; U, urine; B, blood; BM, bone marrow; L,
  leukocytes; F, fibroblasts; S, serum; P, plasma; E, enzyme activity;
  M, molecular; Pd, pseudodeficiency
# Source :: https://humgenomics.biomedcentral.com/articles/10.1186/1479-7364-5-3-156

[fn:glb1]GM1 and MPS-IVB appear to be a continuum of phenotypes
[fn:ncs]p-nitrocatecol sulfate is used for ARSA(MLD) and
ARSB(MPS-VI) arylsulfatase assays. ARSB is inactivated with
0.25M sodium pyrophosphate. ARSA is inactivated with barium
[fn:b1]Patients with the B1 variant produce Hex A, which is normal
when tested with artificial substrates, but defective with natural
substrates
[fn:acarbose]GAA measurement in leukocytes is unreliable due to
neutral \alpha-glucosidase activity in acidic conditions. Acarbose can
be used to inhibit neutral \alpha-glucosidase activity in leukocytes
[fn:ppca]Leads to \beta-galactosidase and neuraminidase deficiency
[fn:msd]Decreased activity of multiple sulfatases
[fn:icell]Activity of MPR targeted lysosomal hydrolases is elevated in
plasma and decreased in cultured fibroblasts
[fn:chito]5-7% of the population have an AR defect in the
chitotriosidase gene, which leads to false-negative values
[fn:all]ML-II & III are allelic, extremes in a spectrum of severity

* COMMENT NBS table

#+CAPTION[]:LSDs Suggested for NBS
#+NAME: tab:lsdnbs
#+ATTR_LATEX: :environment longtable :float sideways
| Diseases    | Enzyme                     | Clinical Features                    | Substrates/Tissues          | Labelled Substrate              | MS/MS Substrates                   |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| Fabry       | \alpha-galactosidase A     | Extremity pain and paresthesias,     | Glycosphingolipids-         | 4-MU-\alpha-galactoside         | Lipidated \alpha-galacoside with   |
|             | GLA                        | angiokeratoma, hypohidrosis,         | globotriaosylcaramide       |                                 | /N/-linked /t/-butyloxycarbamido   |
|             |                            | corneal opacity, deteriorating       | and galabiosylceramide,     | *Both enzyme and DNA are        | group                              |
|             |                            | renal function                       | blood group B substances    | recommended for detecting       |                                    |
|             |                            |                                      | in body fluid, blood        | female Fabry patients           |                                    |
|             |                            |                                      | vessels, heart, kidney and  |                                 |                                    |
|             |                            |                                      | eyes                        |                                 |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| Gaucher     | \beta-glucocerebrosidase   | Type I: Bone                         | Glucocerebroside in all     | 4-MU-\beta-D-glucoside          | C12-glucosylceremide               |
|             | GBA                        | lesions, hepatosplenomegaly,         | organs, including spleen,   |                                 |                                    |
|             |                            | anemia and thrombocytopenia,         | bone marrow and lymph       |                                 |                                    |
|             |                            | lung disease.                        | nodes                       |                                 |                                    |
|             |                            | Type II: Neurodegeneration and       |                             |                                 |                                    |
|             |                            | hepatosplenomegaly in infancy        |                             |                                 |                                    |
|             |                            | Type III: Intermediate between I     |                             |                                 |                                    |
|             |                            | and II                               |                             |                                 |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| Krabbe      | \beta-galactocerebrosidase | Extreme irritability, rapid mental   | Galactocerebroside and      | H^{3} labeled                   | C8-galactosylceremide              |
|             | GALC                       | and motor degeneration, spastic      | psychosine in myelin        | Galactosylceramide              |                                    |
|             |                            | quadriplegia, blindness without      | sheath only                 |                                 |                                    |
|             |                            | organomegaly                         |                             | 6-Hexadecanoylamino-4-          |                                    |
|             |                            |                                      |                             | MU-\beta-D-galactoside          |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| MPS-I       | \alpha-L-iduronidase       | Coarse facial features, umbilical    | Dermatan sulfate (DS)       | 4-MU-\alpha-L-iduronide         | Umbelliferyl-\alpha-L-iduronide    |
| (Hurler,    | IDUA                       | or inguinal hernia, impaired         | and heparan sulfate (HS)    |                                 | attached to a four carbon          |
| H/S,        |                            | mental development,                  | in all organs, specifically |                                 | linker with terminal               |
| Scheie)     |                            | corneal clouding, dysostosis         | CNS, joint/skeletal, heart, |                                 | /t/-butyloxycarbamido group        |
|             |                            | multiplex, short stature, hearing    | eye, liver, spleen          |                                 |                                    |
|             |                            | loss, cardiomyopathy; only           |                             |                                 |                                    |
|             |                            | somatic features in mild form        |                             |                                 |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| MPS-II      | iduronate-2-sulfatase      | Similar features as MPS-I: coarse    | Dermatan sulfate,           | 4-MU-1-iduronide-2-             | Umbelliferyl-\alpha-L-iduronide-2- |
| (Hunter)    | IDS                        | facial features, stiff joints, short | heparan sulfate in all      | sulfate                         | sulfate attached to a five         |
|             |                            | statue, progressive cognitive        | organs, specifically CNS,   |                                 | carbon linker with terminal        |
|             |                            | deterioration, dysostosis            | joint/skeletal, heart, eye, |                                 | /t/-butyloxycarbamido group        |
|             |                            | multiplex. No corneal clouding.      | liver and spleen            |                                 |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| MPS-IVA     | N-acetyl-galactosamine-    | Dwarfism, distinct skeletal          | Gal-6S from Keratan         | H^{3} labeled 6-sulfo-N-        | Umbelliferyl-\beta-D-galactose-6-  |
| (Morquio A) | 6-sulfatase                | dysplasia (genu valgum,              | sulfate and GalNAc-6S       | acetylglactosamine-             | sulfate attached to a five-        |
|             | GALNS                      | pectuscarinatum, kyphosis,           | from chondroitin 6-         | glucuronic acid-6-sulfo-N-      | carbon linker with a terminal      |
|             |                            | odontoid hypoplasia,                 | sulfate in Joint/skeletal,  | acetyl galactosaminitol         | /t/-butyloxycarbamido group        |
|             |                            | pectuscarinatum), corneal            | heart, respiratory and eye  |                                 |                                    |
|             |                            | clouding. Normal intellectual        |                             | 4-MU-\beta-D-galactoside-6-     |                                    |
|             |                            | abilities.                           |                             | sulphate                        |                                    |
|             |                            |                                      |                             | (Determine \beta-galactosidase  |                                    |
|             |                            |                                      |                             | activity to differentiate MPS   |                                    |
|             |                            |                                      |                             | IVB)                            |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| MPS-VI      | arylsulfatase B            | Similar somatic features as MPS      | Dermatan sulfate in         | /p/-nitrocatecol sulfate,       | Umbelliferyl-2-acetamido-D-        |
| (Maroteaux- | ARSB                       | I: short stature, restricted joint   | joint/skeletal, heart,      | subtraction of arylsulfatase    | galactose-4-sulfate attached       |
| Lamy)       |                            | movement, corneal clouding,          | respiratory and eye         | A (ARSA) activity from total    | to a six carbon linker with a      |
|             |                            | dysostosis multiplex, and            |                             | reaction                        | terminal /t/-butyloxycarbamido     |
|             |                            | hepatomegaly. No neurological        |                             |                                 | group                              |
|             |                            | defects.                             |                             | H^{3} labeled substrate derived |                                    |
|             |                            |                                      |                             | from chondroitin 4-sulfate      |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| NP-A&B      | acid sphingomyelinase      | Type A: Massive                      | Sphingomyelin and           | C^{14}-labeled sphingomyelin    | C6-sphingomyelin                   |
|             | ASM                        | hepatosplenomegaly withrapid         | cholesterol in CNS,         |                                 |                                    |
|             |                            | neurodegenerationin infancy.         | spleen, lymph nodes,        | 6-Hexadecanoylamino-4-          |                                    |
|             |                            | Type B: hepatomegaly, restrictive    | bone marrow, lung and       | MU-phosphorylcholine            |                                    |
|             |                            | lung disease and hyperlipidemia      | liver                       |                                 |                                    |
|             |                            | in childhood. Normal                 |                             |                                 |                                    |
|             |                            | intelligence.                        |                             |                                 |                                    |
|-------------+----------------------------+--------------------------------------+-----------------------------+---------------------------------+------------------------------------|
| Pompe       | acid \alpha-glucosidase    | Infantile form:                      | Glycogen in cardiac and     | 4-MU-\alpha-D-glucoside         | Lipidated \alpha-D-glucoside with  |
| (GSD II)    | GAA                        | Hypotonia,cardiomegaly and           | skeletal muscles            |                                 | N-linked /t/-butyloxycarbamido     |
|             |                            | hypertrophic cardiomyopathy,         |                             |                                 | group                              |
|             |                            | hepatomegaly, severe muscle          |                             |                                 |                                    |
|             |                            | weakness, respiratory failure,       |                             |                                 |                                    |
|             |                            | macroglossia.                        |                             |                                 |                                    |
|             |                            | Late-onset form: Progressive         |                             |                                 |                                    |
|             |                            | muscle weakness.                     |                             |                                 |                                    |


# Source :: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902264/
